{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:23:43Z","timestamp":1761920623202,"version":"3.37.3"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,7,10]],"date-time":"2019-07-10T00:00:00Z","timestamp":1562716800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,7,10]],"date-time":"2019-07-10T00:00:00Z","timestamp":1562716800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s10549-019-05343-4","type":"journal-article","created":{"date-parts":[[2019,7,10]],"date-time":"2019-07-10T15:02:54Z","timestamp":1562770974000},"page":"767-770","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Double heterozygous mutation in the BRCA1 and ATM genes involved in development of primary metachronous tumours: a case report"],"prefix":"10.1007","volume":"177","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4315-415X","authenticated-orcid":false,"given":"Raquel","family":"Andr\u00e9s","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Menao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Arruebo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Qu\u00edlez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Jos\u00e9","family":"Cardiel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,7,10]]},"reference":[{"issue":"suppl 5","key":"5343_CR1","doi-asserted-by":"publisher","first-page":"v103","DOI":"10.1093\/annonc\/mdw327","volume":"27","author":"S Paluch-Shimon","year":"2016","unstructured":"Paluch-Shimon S, Cardoso F, Sessa C, Balmana J, Cardoso MJ, Gilbert F, Senkus E, ESMO Guidelines Committee (2016) Prevention and screening in BRCA mutation carriers and other breast\/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening. Ann Oncol 27(suppl 5):v103\u2013v110","journal-title":"Ann Oncol"},{"issue":"12","key":"5343_CR2","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1007\/s12094-015-1435-3","volume":"17","author":"G Llort","year":"2015","unstructured":"Llort G, Chirivella I, Morales R, Serrano R, Sanchez AB, Teul\u00e9 A, Lastra E, Brunet J, Balma\u00f1a J, Gra\u00f1a B, SEOM Hereditary Cancer Working Group (2015) SEOM clinical guidelines in hereditary breast and ovarian cancer. Clin Transl Oncol 17(12):956\u2013961","journal-title":"Clin Transl Oncol"},{"key":"5343_CR3","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1056\/NEJMsr1501341","volume":"372","author":"DF Easton","year":"2015","unstructured":"Easton DF, Pharoah PD, Antoniou AC, Tischkowitz M, Tavtigian SV, Nathanson KL, Devilee P, Meindl A, Couch FJ, Southey M, Goldgar DE, Evans DG, Chenevix-Trench G, Rahman N, Robson M, Domchek SM, Foulkes WD (2015) Gene-panel sequencing and the prediction of breast-cancer risk. N Engl J Med 372:2243\u20132257","journal-title":"N Engl J Med"},{"issue":"1","key":"5343_CR4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/cncr.29010","volume":"121","author":"N Tung","year":"2015","unstructured":"Tung N, Battelli C, Allen B et al (2015) Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel. Cancer 121(1):25\u201333","journal-title":"Cancer"},{"issue":"5","key":"5343_CR5","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s12282-012-0432-4","volume":"22","author":"T Nomizu","year":"2015","unstructured":"Nomizu T, Matsuzaki M, Katagata N, Kobayashi Y, Sakuma T, Monma T, Saito M, Watanabe F, Midorikawa S, Yamaguchi Y (2015) A case of familial breast cancer with double heterozygosity for BRCA1 and BRCA2 genes. Breast Cancer 22(5):557\u2013561","journal-title":"Breast Cancer"},{"issue":"3","key":"5343_CR6","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1007\/s10549-012-2050-4","volume":"134","author":"S Heidemann","year":"2012","unstructured":"Heidemann S, Fischer C, Engel C, Fischer B, Harder L, Schlegelberger B, Niederacher D, Goecke TO, Doelken SC, Dikow N, Jonat W, Morlot S, Schmutzler RC, Arnold NK (2012) Double heterozygosity for mutations in BRCA1 and BRCA2 in German breast cancer patients: implications on test strategies and clinical management. Breast Cancer Res Treat 134(3):1229\u20131239","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"5343_CR7","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s10549-010-0853-8","volume":"124","author":"M Zuradelli","year":"2010","unstructured":"Zuradelli M, Peissel B, Manoukian S, Zaffaroni D, Barile M, Pensotti V, Cavallari U, Masci G, Mariette F, Benski AC, Santoro A, Radice P (2010) Four new cases of double heterozygosity for BRCA1 and BRCA2 gene mutations: clinical, pathological, and family characteristics. Breast Cancer Res Treat 124(1):251\u2013258","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"5343_CR8","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s10549-014-2971-1","volume":"145","author":"AP Sokolenko","year":"2014","unstructured":"Sokolenko AP, Bogdanova N, Kluzniak W, Preobrazhenskaya EV, Kuligina ES, Iyevleva AG, Aleksakhina SN, Mitiushkina NV, Gorodnova TV, Bessonov AA, Togo AV, Lubi\u0144ski J, Cybulski C, Jakubowska A, D\u00f6rk T, Imyanitov EN (2014) Double heterozygotes among breast cancer patients analyzed for BRCA1, CHEK2, ATM, NBN\/NBS1, and BLM germ-line mutations. Breast Cancer Res Treat 145(2):553\u2013562","journal-title":"Breast Cancer Res Treat"},{"issue":"23","key":"5343_CR9","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","volume":"317","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker KB, Hopper JL, Barnes DR et al (2017) Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317(23):2402\u20132416","journal-title":"JAMA"},{"key":"5343_CR10","doi-asserted-by":"publisher","first-page":"R142","DOI":"10.1186\/bcr3347","volume":"14","author":"SY Phuah","year":"2012","unstructured":"Phuah SY, Looi LM, Hassan N, Rhodes A, Dean S, Taib NA et al (2012) Triple-negative breast cancer and PTEN (phosphatase and tensin homologue) loss are predictors of BRCA1 germline mutations in women with early-onset and familial breast cancer, but not in women with isolated late-onset breast cancer. Breast Cancer Res 14:R142","journal-title":"Breast Cancer Res"},{"key":"5343_CR11","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1158\/1055-9965.EPI-11-0775","volume":"21","author":"N Mavaddat","year":"2012","unstructured":"Mavaddat N, Barrowdale D, Andrulis IL, Domchek SM, Eccles D, Nevanlinna H et al (2012) Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the consortium of investigators of modifiers of BRCA1\/2 (CIMBA). Cancer Epidemiol Biomark Prev 21:134\u2013147","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"2","key":"5343_CR12","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/cncr.29041","volume":"121","author":"MS Jacqueline Mersch","year":"2015","unstructured":"Jacqueline Mersch MS (2015) Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian. Cancer 121(2):269\u2013275","journal-title":"Cancer"},{"key":"5343_CR13","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1126\/science.286.5442.1162","volume":"286","author":"D Cortez","year":"1999","unstructured":"Cortez D, Wang Y, Qin J, Elledge SJ (1999) Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. Science 286:1162\u20131166","journal-title":"Science"},{"issue":"9","key":"5343_CR14","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1001\/jamaoncol.2017.0424","volume":"3","author":"FJ Couch","year":"2017","unstructured":"Couch FJ, Shimelis H, Hu Ch et al (2017) Associations between cancer predisposition testing panel genes and breast cancer. JAMA Oncol 3(9):1190\u20131196","journal-title":"JAMA Oncol"},{"issue":"19","key":"5343_CR15","doi-asserted-by":"publisher","first-page":"8736","DOI":"10.1158\/0008-5472.CAN-05-1598","volume":"65","author":"TJ Bowen","year":"2005","unstructured":"Bowen TJ, Yakushiji H, Montagna C, Jain S, Ried T, Wynshaw-Boris A (2005) Atm heterozygosity cooperates with loss of Brca1 to increase the severity of mammary gland cancer and reduce ductal branching. Cancer Res 65(19):8736\u20138746","journal-title":"Cancer Res"},{"key":"5343_CR16","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1748-717X-5-15","volume":"5","author":"F Su","year":"2010","unstructured":"Su F, Smilenov LB, Ludwig T et al (2010) Hemizygosity for Atm and Brca1 influence the balance between cell transformation and apoptosis. Radiat Oncol 5:15\u201323","journal-title":"Radiat Oncol"},{"issue":"1","key":"5343_CR17","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/1748-717X-6-96","volume":"6","author":"J Wang","year":"2011","unstructured":"Wang J, Su F, Smilenov LB, Zhou L, Hu W, Ding N, Zhou G (2011) Mechanisms of increased risk of tumorigenesis in Atm and Brca1 double heterozygosity. Radiat Oncol 6(1):96","journal-title":"Radiat Oncol"},{"issue":"2","key":"5343_CR18","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s10549-014-2971-1","volume":"145","author":"AP Sokolenko","year":"2014","unstructured":"Sokolenko AP, Bogdanova N, Kluzniak W et al (2014) Double heterozygotes among breast cancer patients analyzed for BRCA1, CHEK2, ATM, NBN\/NBS1, and BLM germ-line mutations. Breast Cancer Res Treat 145(2):553\u2013562","journal-title":"Breast Cancer Res Treat"},{"key":"5343_CR19","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1007\/s10549-012-2050-4","volume":"134","author":"S Heidemann","year":"2012","unstructured":"Heidemann S, Fischer C, Engel C et al (2012) Double heterozygosity for mutations in BRCA1 and BRCA2 in German breast cancer patients: implications on test strategies and clinical management. Breast Cancer Res Treat 134:1229\u20131239","journal-title":"Breast Cancer Res Treat"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-019-05343-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-019-05343-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-019-05343-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T23:20:29Z","timestamp":1594250429000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-019-05343-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,10]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["5343"],"URL":"https:\/\/doi.org\/10.1007\/s10549-019-05343-4","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"type":"print","value":"0167-6806"},{"type":"electronic","value":"1573-7217"}],"subject":[],"published":{"date-parts":[[2019,7,10]]},"assertion":[{"value":"25 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All the authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}